Latest Conference

Badr Ratnakaran, MBBS, highlights the growing loneliness epidemic and emphasizes its severe impact on mental and physical health at the 2025 APA Annual Meeting.

Resilience: how does it improve overall health? Helen Lavretsky, MD, shared her thoughts at the 2025 APA Annual Meeting.

Research from the 2025 APA Annual Meeting reveals a strong link between borderline personality disorder and problematic internet use, highlighting impulsivity and compulsivity in affected individuals.

Attendees at the 2025 APA Annual Meeting are excited to connect with peers and experts, exploring lifestyle medicine and networking opportunities for career growth.

Mental health professionals recognize the profound impact of climate change on anxiety, depression, and overall well-being, urging proactive support for affected patients, says one APA attendee.

Can GLP-1 agonists support patients on antipsychotics? Amir Meftah, MD, and colleagues explore its use.

Angelo Chaia, MD, explores the impact of long-acting injectables on patients with severe mental illness and substance use disorders at the 2025 APA Annual Meeting.

Our board members are presenting at this year's APA Annual Meeting. Be sure to check out their sessions!

Vincenzo Di Nicola has won the Award for Leadership in Child, Adolescent, and Young Adult Psychiatry. Learn more about his thoughts on trauma, leadership, and issues in child and adolescent psychiatry.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

Learn more about the findings from the first 3 EMERGENT trials, and their use in the 4th and 5th trials, presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.

A new phase 2 trial reveals a novel antidepressant delivers rapid symptom relief for major depressive disorder, with patients experiencing significant improvement within just hours of their first dose.

Check out some of the top clinical pearls gleaned from presenters at Real Psychiatry.

Check out 2 high-level examples of patient quality of life improvement following treatment for tardive dyskinesia.

What are the signs of increased struggle with tardive dyskinesia? Here's what Erin Crown, MHS, PA-C, Psych-CAQ, picks up on during patient visits.

Tardive dyskinesia can be difficult to discern...

Here's how to address medication side effects with patients.

COVID-19 increased the usage of telemedicine drastically, but is that always a good thing?

What 5 factors should you look at when selecting ADHD treatment?

Let's explore COVID-19's impact on psychiatric research...

Let's define success for patients with ADHD...

"Who are you important to? If you passed tomorrow, who would show up at your funeral?"

When a patient has comorbidities like anxiety, substance use, and depression, how can you best select a treatment?

Come celebrate the evolution of Psychiatric Times and psychiatry as a whole!

When prescribing ADHD medications, when is the best time to switch treatments?

How can we improve patient outcomes? Collaboration.